Congress Materials – Congress of Clinical Rheumatology (CCR West 2025)
2025 Congress of Clinical Rheumatology | Sep 18-21 | Huntington Beach, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
This document will be available after September 18 2025
Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available after September 18 2025
Icotrokinra in Patients with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis
Joseph F. Merola, Philip J. Mease, Laura C. Coates, Iain B. McInnes, Peter Nash, Alexis Ogdie, Lihi Eder, Mitsumasa Kishimoto, Anna Beutler, Konstantina Psachoulia, Shihong Sheng, Bei Zhou, Mehrdad Javidi, Chandni Valiathan, Charles Iaconangelo, Ya-Wen Yang, Arun Kannan, Chetan S. Karyekar, Tasneam Shagroni
This document will be available after September 18 2025
Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior TNF Inhibitor
Alice B. Gottlieb, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alexis Ogdie
This document will be available after September 18 2025
Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase3b/Randomized/Double-Blind/Placebo-Controlled APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available after September 18 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors
Philip J. Mease, Jessica Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available after September 18 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J. Mease, Jessica Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available after September 18 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
